|
1.
|
|
12 p, 909.2 KB |
The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease
/
Biondetti, Emma (Team "Movement Investigations and Therapeutics") ;
Santin, Mathieu D. (Centre de NeuroImagerie de Recherche) ;
Valabrègue, Romain (Centre de NeuroImagerie de Recherche) ;
Mangone, Graziella (Assistance Publique Hôpitaux de Paris) ;
Gaurav, Rahul (Team "Movement Investigations and Therapeutics") ;
Pyatigorskaya, Nadya (Assistance Publique Hôpitaux de Paris) ;
Hutchison, Matthew (Biogen (Estats Units d'Amèrica)) ;
Yahia-Cherif, Lydia (Centre de NeuroImagerie de Recherche) ;
Villain, Nicolas (Assistance Publique Hôpitaux de Paris) ;
Habert, Marie-Odile (Sorbonne Université) ;
Arnulf, Isabelle (Assistance Publique Hôpitaux de Paris) ;
Leu-Semenescu, Smaranda (Hôpital Pitié-Salpêtrière) ;
Dodet, Pauline (Assistance Publique Hôpitaux de Paris) ;
Vila Bover, Miquel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Corvol, Jean-Christophe (Assistance Publique Hôpitaux de Paris) ;
Vidailhet, Marie (Assistance Publique Hôpitaux de Paris) ;
Lehéricy, Stéphane (Assistance Publique Hôpitaux de Paris) ;
Universitat Autònoma de Barcelona
In Parkinson's disease, there is a progressive reduction in striatal dopaminergic function, and loss of neuromelanin-containing dopaminergic neurons and increased iron deposition in the substantia nigra. [...]
2021 -  10.1093/brain/awab191
Brain, Vol. 144 (may 2021) , p. 3114-3125
|
|
|
2.
|
|
|
3.
|
|
18 p, 8.5 MB |
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates
/
Bourdenx, M. (CNRS) ;
Nioche, A. (Institut Jean Nicod, Département d'études cognitives, CNRS, UMR 8129, Paris, France) ;
Dovero, S. (CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France) ;
Arotcarena, M.-L. (CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France) ;
Camus, S. (CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France) ;
Porras, G. (CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France) ;
Thiolat, M.-L. (CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France) ;
Rougier, N. P. (INRIA Bordeaux Sud-Ouest, 33405 Talence, France) ;
Prigent, A. (CHU Nantes, Department of Neurology, Nantes F-44093, France) ;
Aubert, P. (CHU Nantes, Department of Neurology, Nantes F-44093, France) ;
Bohic, S. (EA-7442 Rayonnement Synchrotron et Recherche Medicale, RSRM, University of Grenoble Alpes, 38000 Grenoble, France) ;
Sandt, C. (SMIS beamline, Synchrotron SOLEIL, l'orme des merisiers, 91192 Gif sur Yvette, France) ;
Laferrière, F. (CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France) ;
Doudnikoff, E. (CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France) ;
Kruse, N. (University Medical Center Goettingen, Institute of Neuropathology, Goettingen, Germany) ;
Mollenhauer, B. (University Medical Center Goettingen, Institute of Neuropathology, Goettingen, Germany) ;
Novello, S. (Neuroscience Center and National Institute of Neuroscience, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy) ;
Morari, M. (Neuroscience Center and National Institute of Neuroscience, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy) ;
Leste-Lasserre, T. (INSERM, Neurocentre Magendie, U1215, Physiopathologie de la Plasticité Neuronale, F-33000 Bordeaux, France) ;
Trigo-Damas, I. (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Goillandeau, M. (CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France) ;
Perier, Celine (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Estrada, C. (Institute of Research on Aging (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain) ;
Garcia-Carrillo, N. (Centro Experimental en Investigaciones Biomédica (CEIB), Universidad de Murcia, Murcia, Spain) ;
Recasens, A. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vaikath, N. N. (Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Education City, Qatar) ;
El-Agnaf, O. M. A. (Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Education City, Qatar) ;
Herrero, M. T. (Universidad de Múrcia) ;
Derkinderen, Pascal (CHU Nantes, Department of Neurology, Nantes F-44093, France) ;
Vila Bover, Miquel (Institució Catalana de Recerca i Estudis Avançats) ;
Obeso, J. A. (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Dehay, B. (CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France) ;
Bezard, E. (CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France) ;
Universitat Autònoma de Barcelona
Machine learning-based approach unravels distinct pathological signatures induced by patient-derived α-synuclein seeds in monkeys. Dopaminergic neuronal cell death, associated with intracellular α-synuclein (α-syn)-rich protein aggregates [termed "Lewy bodies" (LBs)], is a well-established characteristic of Parkinson's disease (PD). [...]
2020 - 10.1126/sciadv.aaz9165
Science advances, Vol. 6 (may 2020)
|
|
|
4.
|
|
6 p, 2.1 MB |
Chitinase 3-like 1 is neurotoxic in primary cultured neurons
/
Matute-Blanch, Clara (Hospital Universitari Vall d'Hebron) ;
Calvo-Barreiro, Laura (Hospital Universitari Vall d'Hebron) ;
Carballo-Carbajal, Iria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gonzalo, Ricardo (Hospital Universitari Vall d'Hebron) ;
Sánchez, Alex (Universitat de Barcelona. Departament de Genètica, Microbiologia i Estadística) ;
Vila Bover, Miquel (Institució Catalana de Recerca i Estudis Avançats) ;
Montalban, Xavier (St. Michael's Hospital, University of Toronto) ;
Comabella, Manuel (Hospital Universitari Vall d'Hebron)
UDHEBRON.
Chitinase 3-like 1 (CHI3L1) is known to play a role as prognostic biomarker in the early stages of multiple sclerosis (MS), and patients with high cerebrospinal fluid CHI3L1 levels have an increased risk for the development of neurological disability. [...]
2020 - 10.1038/s41598-020-64093-2
Scientific reports (Nature Publishing Group), Vol. 10 (april 2020)
|
|
|
5.
|
|
18 p, 6.5 MB |
Bioinspired theranostic coordination polymer nanoparticles for intranasal dopamine replacement in parkinson's disease
/
Garcia-Pardo, Javier (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Novio Vázquez, Fernando (Universitat Autònoma de Barcelona. Departament de Química) ;
Nador, Fabiana (Institut Català de Nanociència i Nanotecnologia) ;
Cavaliere, Ivana (Institut Català de Nanociència i Nanotecnologia) ;
Suárez García, Salvio (Institut Català de Nanociència i Nanotecnologia) ;
Lope-Piedrafita, Silvia (Universitat Autònoma de Barcelona. Servei de Ressonància Magnètica Nuclear) ;
Candiota Silveira, Ana Paula (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Romero-Gimenez, Jordi (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rodríguez-Galván, Beatriz (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Bové, Jordi (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vila Bover, Miquel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Lorenzo Rivera, Julia (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Ruiz-Molina, Daniel (Institut Català de Nanociència i Nanotecnologia)
Dopamine (DA) is one of the main neurotransmitters found in the central nervous system and has a vital role in the function of dopaminergic (DArgic) neurons. A progressive loss of this specific subset of cells is one of the hallmarks of age-related neurodegenerative disorders such as Parkinson's disease (PD). [...]
2021 - 10.1021/acsnano.1c00453
ACS nano, Vol. 15, issue 5 (May 2021) , p. 8592-8609
|
|
|
6.
|
|
8 p, 1.0 MB |
Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder
/
Laguna, Ariadna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Xicoy, Helena (Donders Institute for Brain) ;
Tolosa, Eduardo (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Serradell, Mònica (Hospital Clínic i Provincial de Barcelona) ;
Vilas, Dolores (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gaig, Carles (Hospital Clínic i Provincial de Barcelona) ;
Fernández, Manel (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Yanes, Oscar (Universitat Rovira i Virgili) ;
Santamaria, Joan (Hospital Clínic i Provincial de Barcelona) ;
Amigó, Núria (Biosfer Teslab, Reus) ;
Iranzo, Alex (Hospital Clínic i Provincial de Barcelona) ;
Vila Bover, Miquel (Institució Catalana de Recerca i Estudis Avançats) ;
Universitat Autònoma de Barcelona
Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of Lewy-type synucleinopathies (LTS), which can present either with an initial predominant parkinsonism (Parkinson's disease (PD)) or dementia (dementia with Lewy bodies (DLB)). [...]
2021 - 10.1038/s41531-021-00184-9
NPJ Parkinson's disease, Vol. 7 (may 2021)
|
|
|
7.
|
|
2 p, 313.7 KB |
Correction to : The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity
/
Kim, Hanna (The University of Alabama. Department of Biological Sciences) ;
Calatayud, Carles (Institut d'Investigació Biomèdica de Bellvitge) ;
Guha, Sanjib (Buck Institute for Age Research) ;
Fernandez Carasa, Irene (Universitat de Barcelona. Institut de Biomedicina) ;
Berkowitz, Laura (University of Alabama. Department of Biological Sciences) ;
Carballo-Carbajal, Iria (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Ezquerra, Mario (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Fernández-Santiago, Rubén (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Kapahi, Pankaj (Buck Institute for Age Research) ;
Raya, Ángel (Institució Catalana de Recerca i Estudis Avançats) ;
Miranda Vizuete, Antonio (Instituto de Biomedicina de Sevilla) ;
Lizcano de Vega, José Miguel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Vila Bover, Miquel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Caldwell, Kim A. (University of Alabama. Department of Biological Sciences) ;
Caldwell, Guy A. (University of Alabama. Department of Biological Sciences) ;
Consiglio, Antonella (Università degli Studi di Brescia. Dipartimento di Medicina Molecolare e Traslazionale) ;
Dalfo, Esther (Universitat Autònoma de Barcelona. Institut de Neurociències)
2018 - 10.1007/s12035-018-1010-3
Molecular neurobiology, Vol. 55 (april 2018) , p. 7553-7554
|
|
|
8.
|
|
20 p, 1.6 MB |
Autophagic- and Lysosomal-Related Biomarkers for Parkinson's Disease : Lights and Shadows
/
Xicoy, Helena (Department of Molecular Animal Physiology, Donders Institute for Brain, Cognition and Behaviour, Donders Centre for Neuroscience, Faculty of Science, 6525 GA Nijmegen, The Netherlands) ;
Peñuelas, Núria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vila Bover, Miquel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Laguna, Ariadna (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Parkinson's disease (PD) is a neurodegenerative disorder that currently affects 1% of the population over the age of 60 years, for which no disease-modifying treatments exist. This lack of effective treatments is related to the advanced stage of neurodegeneration existing at the time of diagnosis. [...]
2019 - 10.3390/cells8111317
Cells, Vol. 8 (october 2019)
|
|
|
9.
|
|
23 p, 4.3 MB |
Sex-dependent calcium hyperactivity due to lysosomal-related dysfunction in astrocytes from APOE4 versus APOE3 gene targeted replacement mice
/
Larramona-Arcas, Raquel (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
González-Arias, Candela (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Perea, Gertrudis (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Gutiérrez, Antonia (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Vitorica, Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
García-Barrera, Tamara (Universidad de Huelva. Departamento de Química, Facultad de Ciencias Experimentales) ;
Gómez-Ariza, José Luis (Universidad de Huelva. Departamento de Química, Facultad de Ciencias Experimentales) ;
Pascua-Maestro, Raquel (Instituto de Biología y Genética Molecular, Universidad de Valladolid-CSIC. Departamento de Bioquímica y Biología Molecular y Fisiología) ;
Ganfornina, María Dolores (Instituto de Biología y Genética Molecular, Universidad de Valladolid-CSIC. Departamento de Bioquímica y Biología Molecular y Fisiología) ;
Kara, Eleanna (Present Address: Institute of Neuropathology, University Hospital of Zurich) ;
Hudry, Eloise (Alzheimer's Disease Research Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School) ;
Martinez-Vicente, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vila Bover, Miquel (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Galea, Elena (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Masgrau Juanola, Roser (Universitat Autònoma de Barcelona. Institut de Neurociències)
The apolipoprotein E (APOE) gene exists in three isoforms in humans: APOE2, APOE3 and APOE4. APOE4 causes structural and functional alterations in normal brains, and is the strongest genetic risk factor of the sporadic form of Alzheimer's disease (LOAD). [...]
2020 - 10.1186/s13024-020-00382-8
Molecular neurodegeneration, Vol. 15 (june 2020)
|
|
|
10.
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
